France Anti Aging Therapeutics Market Report 2022 to 2030

France Anti Aging Therapeutics Market Analysis

$ 3999

France anti-aging therapeutics market is expected to witness growth from $17 Mn in 2022 to $53 Mn in 2030 with a CAGR of 15.53% for the year 2022-2030. The presence of robust research and development industry in France makes it a popular destination for the testing of anti-aging therapeutics thereby resulting in the growth of the market. The France anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the key players in the market include Cottos, DBV Technologies, and Allergan.

ID: IN10FRPH030 CATEGORY: Pharmaceuticals GEOGRAPHY: France

Buy Now

France Anti-Aging Therapeutics Market Executive Summary

The France anti-aging therapeutics market size is at around $17 Mn in 2022 and is projected to reach $53 Mn in 2030, exhibiting a CAGR of 15.53% during the forecast period. France declared that the budget for 2023 reflects a modest cut in government spending, which will be made possible by changes to pensions and unemployment insurance. In comparison to 2022, public expenditure will account for 56.7% of GDP in 2019. The only expenditure that will keep rising is healthcare. Due to a decrease in the quantity of money required for Covid-related care, the social security spending deficit will drop from $18.97 Bn to $7.25 Bn in 2023. With a broad variety of applications being developed, from drug discovery and medical devices to synthetic biology and green energy, Paris is one of Europe's largest biotech clusters. The French government spent $8 Bn last year in an effort to make France the hub of European health innovation by 2030, and it is anticipated that this trend will continue.

The proportion of French people 65 and older will gradually rise over the coming decades, reaching about 25% in 2030 and nearly 30% in 2050. Ages 85 and elderly will represent a larger share of the population than any other age group, growing from about 1 Mn in the mid-2000s to about 2.5 Mn in 2030. And finally, over the same time span, the number of centennials—from about 15,000 to 60,000—will probably quadruple. Changes in the levels of variability and intricacy of systems are related to aging. According to the constrained disorder principle, aging is defined as having reduced variability or moving outside the limits of variability. Living organisms are defined based on their inherent disorder within arbitrary boundaries. We address the roles of disorder and system variability in the pathogenesis of aging with a focus on associations between variability and the tell-tale signs of aging.

The hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication, are of relevance for developing new interventions for aging. Autophagy, microbiome disruption, changed mechanical properties, splicing dysregulation, and inflammation is recent indicators of aging. The finding that metformin can up to 50% increase the lifespan of the roundworm Caenorhabditis elegans was made in France, and it has allowed for the genetic dissection of the pathways required for metformin longevity effects. It is anticipated that tailored medicine strategies will be used in the future when metformin is used to treat human aging.

France Anti Aging Therapeutics Market

Market Dynamics

Market Growth Drivers Analysis

French consumers are renowned for favoring natural and organic goods, and this tendency is present in the anti-aging market as well. The need for anti-aging products developed with natural and organic ingredients is consequently rising. France has a robust research and development industry, which is producing cutting-edge anti-aging products and therapies like creams based on nanotechnology and minimally invasive surgeries. High-end anti-aging products and treatments are in high demand in France, which is renowned for its luxury market.

Market Restraints

It can be challenging for companies to stand out from the competition and take market share in France's highly competitive anti-aging market, which has a large number of established competitors and new entrants. The development and marketing of anti-aging products may be confined by France's stringent rules regarding the use of specific ingredients in cosmetics.

Competitive Landscape

Key Players

StarkAge Therapeutics (FRA)
ENCEFA (FRA)- By utilizing the identification of a novel biological pathway that is set off by the modulation of the well-known CD38 target, ENCEFA creates ground-breaking anti-aging treatments.
DOMALYS (FRA)
Longevity Hub (FRA)
Cottos (FRA)
DBV Technologies (FRA)
Allergan
Ipsen
Lanzhou Institute
Corneal
Galderma
LG Life Science
Bohus BioTech
IMEIK
Merck

Healthcare Policies and Regulatory Landscape

The French National Agency for the Safety of Medicines and Health Products (ANSM), a government organization under the direction of the Ministry of Health, is the regulatory authority in charge of approving and regulating anti-aging therapeutics in France. The French Society of Aesthetic Medicine (SFME), in addition to the ANSM, is involved in overseeing anti-aging therapeutics. The SFME is a specialized association for doctors who practice aesthetic medicine, and they offer direction and suggestions for the use of anti-aging remedies and goods.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Aging Therapeutics Market Segmentation

By Product (Revenue, USD Billion):

Anti-Wrinkle
Hair Color
Ultraviolet (UV) Absorption
Anti-Stretch Mark
Others

By Treatment (Revenue, USD Billion):

Hair Restoration
Anti-Pigmentation
Adult Acne Therapy
Breast Augmentation
Liposuction
Chemical Peel
Others

By Target Group (Revenue, USD Billion):

Male
Female

By Type of Aging (Revenue, USD Billion):

Cellular Aging
Immune Aging
Metabolic Aging
Others

By Type of Molecules (Revenue, USD Billion):

Biologics
Small Molecules

By Mechanism of Action (Revenue, USD Billion):

Senolytic
Cell Regeneration
mTOR inhibitor/Modulator
AMP-kinase/AMP Activator
Mitochondria Inhibitor/Modulator
Others

By Ingredient (Revenue, USD Billion):

Retinoid
Hyaluronic Acid
Alpha Hydroxy Acid
Others

By Distribution Channel (Revenue, USD Billion):

Pharmacies
Stores
Online Stores

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.